Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer

被引:14
|
作者
Wada, Miku [1 ]
Kukita, Asako [1 ]
Sone, Kenbun [1 ]
Hamamoto, Ryuji [2 ,3 ]
Kaneko, Syuzo [2 ]
Komatsu, Masaaki [2 ,3 ]
Takahashi, Yu [1 ]
Inoue, Futaba [1 ]
Kojima, Machiko [1 ]
Honjoh, Harunori [1 ]
Taguchi, Ayumi [1 ]
Kashiyama, Tomoko [1 ]
Miyamoto, Yuichiro [1 ]
Tanikawa, Michihiro [1 ]
Tsuruga, Tetsushi [1 ]
Mori-Uchino, Mayuyo [1 ]
Wada-Hiraike, Osamu [1 ]
Osuga, Yutaka [1 ]
Fujii, Tomoyuki [1 ]
机构
[1] Univ Tokyo, Dept Obstet & Gynecol, Fac Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan
[2] Natl Canc Ctr, Div Mol Modificat & Canc Biol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan
[3] RIKEN Ctr Adv Intelligence Project, Canc Translat Res Team, Chuo Ku, 1-4-1 Nihonbashi, Tokyo 1030027, Japan
关键词
epigenetic modifier; histone methyltransferase; SETD8; high-grade serous ovarian cancer; UNC0379; HISTONE; METHYLATION; P53; ACTIVATION; EXPRESSION;
D O I
10.3390/biom10121686
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The histone methyltransferase SETD8, which methylates the lysine 20 of histone H4 (H4K20), is reportedly involved in human carcinogenesis along with nonhistone proteins such as p53. However, its expression profiles and functions in the context of high-grade serous ovarian carcinoma (HGSOC) are still unknown. The purpose of this study was to investigate the role of SETD8 in HGSOC. We performed quantitative real-time PCR and immunohistochemistry to detect the expression of SETD8 in HGSOC samples and normal ovarian specimens. Then, we assessed the effect of the inhibition of SETD8 expression using small interfering RNA (siRNA) and a selective inhibitor (UNC0379) on cell proliferation and apoptosis in HGSOC cells. The expression of SETD8 was significantly upregulated in clinical ovarian cancer specimens compared to that in the corresponding normal ovary. In addition, suppression of SETD8 expression in HGSOC cells with either siRNA or UNC0379 resulted in reduced levels of H4K20 monomethylation, inhibition of cell proliferation, and induction of apoptosis. Furthermore, UNC0379 showed a long-term antitumor effect against HGSOC cells, as demonstrated by colony-formation assays. SETD8 thus constitutes a promising therapeutic target for HGSOC, warranting further functional studies.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 50 条
  • [1] Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer
    Matthews, Bayley G.
    Bowden, Nikola A.
    Wong-Brown, Michelle W.
    CANCERS, 2021, 13 (23)
  • [2] Neurotensin signaling pathway as a potential therapeutic target in high-grade serous ovarian cancer
    Norris, E. J.
    DeStephanis, D.
    Zhang, Q.
    Tait, D. L.
    Ganapathi, R.
    Ganapathi, M.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 71 - 71
  • [3] Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer
    Ivan, Cristina
    Hu, Wei
    Bottsford-Miller, Justin
    Zand, Behrouz
    Dalton, Heather J.
    Liu, Tao
    Huang, Jie
    Nick, Alpa M.
    Lopez-Berestein, Gabriel
    Coleman, Robert L.
    Baggerly, Keith A.
    Sood, Anil K.
    GYNECOLOGIC ONCOLOGY, 2013, 128 (03) : 506 - 511
  • [4] The histone methyltransferase SETD8 is a potential therapeutic target for endometrial cancer
    Oki, Shinya
    Sone, Kenbun
    Oda, Katsutoshi
    Hamamoto, Ryuji
    Machino, Hidenori
    Kojima, Machiko
    Kukita, Asako
    Tanikawa, Michihiro
    Nagasaka, Kazunori
    Matsumoto, Yoko
    Osuga, Yutaka
    Fujii, Tomoyuki
    CANCER SCIENCE, 2018, 109 : 616 - 616
  • [5] Credentialing ERalpha as target in high-grade serous ovarian cancer.
    Oesterreich, Steffi
    Anderson, Courtney L.
    Sikora, Matthew J.
    Boisen, Michelle M.
    Ma, Tianzhou
    Tseng, George
    Chandran, Uma
    Christie, Alec
    Park, Yongseok
    Luthra, Soumya
    Haluska, Paul
    Mantia-Smaldone, Gina
    Odunsi, Kunle
    McLean, Karen
    Lee, Adrian
    Ellshaev, Esther
    Edwards, Robert P.
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 122 - 122
  • [6] Aberrant activation of the Hedgehog signalling pathway in high-grade serous ovarian cancer: a potential therapeutic target
    Pounds, R.
    Soo, J.
    Uddin, K.
    Dawson, C.
    Kehoe, S.
    Yap, J.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2018, 125 (08) : E37 - E37
  • [7] KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer
    De Donato, Marta
    Babini, Gabriele
    Mozzetti, Simona
    Buttarelli, Marianna
    Ciucci, Alessandra
    Arduini, Gloria
    De Rosa, Maria Cristina
    Scambia, Giovanni
    Gallo, Daniela
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [8] KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer
    Marta De Donato
    Gabriele Babini
    Simona Mozzetti
    Marianna Buttarelli
    Alessandra Ciucci
    Gloria Arduini
    Maria Cristina De Rosa
    Giovanni Scambia
    Daniela Gallo
    Journal of Experimental & Clinical Cancer Research, 39
  • [9] Investigation of epigenetic regulation in the high-grade serous ovarian carcinogenesis
    Komatsu, Masaaki
    Machino, Hidenori
    Nakamura, Kohei
    Kaneko, Syuzo
    Asada, Ken
    Sone, Kenbun
    Oda, Katsutoshi
    Nakayama, Kentaro
    Kyo, Satoru
    Hamamoto, Ryuji
    CANCER SCIENCE, 2018, 109 : 666 - 666
  • [10] High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
    Lisio, Michael-Antony
    Fu, Lili
    Goyeneche, Alicia
    Gao, Zu-hua
    Telleria, Carlos
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (04)